Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
rEVO Biologics
rEVO Biologics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Atryn
Antithrombin (recombinant)
2009-02-06
Antithrombin iii deficiency
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Antithrombin alfa
cardiopulmonary bypass
,
hemorrhage
,
postoperative hemorrhage
,
pre-eclampsia
,
thrombosis
,
venous thrombosis
,
antithrombin iii deficiency
,
thrombophilia
Benzocaine
antithrombin iii deficiency
,
thrombosis
,
venous thrombosis
Antithrombin iii
cardiopulmonary bypass
,
hemorrhage
,
postoperative hemorrhage
,
pre-eclampsia
,
thrombosis
,
venous thrombosis
,
antithrombin iii deficiency
,
thrombophilia
Serine
cardiopulmonary bypass
,
hemorrhage
,
postoperative hemorrhage
,
pre-eclampsia
,
thrombosis
,
venous thrombosis
,
antithrombin iii deficiency
,
thrombophilia
Sodium chloride
hemorrhage
,
postoperative hemorrhage
,
pre-eclampsia
Coagulation factor viia recombinant human
hemophilia a
,
hemophilia b
Rfviia
hemophilia a
,
hemophilia b
Bolus
cardiopulmonary bypass
,
thrombophilia
,
antithrombin iii deficiency
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use